This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
The prime recovery ship was USS Wasp. The recovery was supported by 10,249 U.S. Department of Defense personnel, 134 aircraft, and 26 ships. Postflight medical examination found the astronauts to be in good health, and no significant physiological changes were found.
==== Clemency ==== In response to the Trump administration's crackdown on immigrants with criminal records, Newsom gave heightened consideration to people in this situation. A pardon can eliminate the grounds for deportation of immigrants who would otherwise be legal permanent residents. Pardon requests from people facing deportation are given expedited review by the state Board of Parole Hearings, per a 2018 California law. In his first acts of clemency as governor, Newsom pardoned seven formerly incarcerated people in May 2019, including two Cambodian refugees facing deportation. He pardoned three men who were attempting to avoid being deported to Cambodia or Vietnam in November 2019. They had separately committed crimes when they were each 19 years old. In December 2019, Newsom granted parole to a Cambodian refugee who had been held in a California prison due to a murder case. Although immigrant rights groups wanted Newsom to end policies allowing the transfer to federal agents, the refugee was turned over for possible deportation upon release. On January 13, 2022, Newsom denied parole to Sirhan Sirhan, Robert F. Kennedy's assassin, who had been recommended for parole by a parole board after serving 53 years in prison. Newsom wrote an op-ed for the Los Angeles Times saying Sirhan "still lacks the insight that would prevent him from making the kind of dangerous and destructive decisions he made in the past.
==== Major Intrinsic Protein ==== The Major Intrinsic Protein (MIP) of the human lens of the eye (Aqp0), after which the MIP family was named, represents about 60% of the protein in the lens cell. In the native form, it is an aquaporin (AQP), but during lens development, it becomes proteolytically truncated. The channel, which normally houses 6-9 water molecules, becomes constricted so only three remain, and these are trapped in a closed conformation. These truncated tetramers form intercellular adhesive junctions (head to head), yielding a crystalline array that mediates lens formation with cells tightly packed as required to form a clear lens. Lipids crystallize with the protein. Ion channel activity has been shown for Aquaporins 0, 1, and 6, Drosophila 'Big Brain' (bib) and plant Nodulin-26. Roles of aquaporins in human cancer have been reviewed as have their folding pathways. AQPs may act as transmembrane osmosensors in red cells, secretory granules and microorganisms. MIP superfamily proteins and variations of their selectivity filters have been reviewed.
== Diabetes == A study at the University of California, San Diego School of Medicine has shown that LTB4 promotes insulin resistance in obese mice. Obesity is the major cause of insulin resistance in type 2 diabetes.
Sources: en.wikipedia.org
In February 2022, Carrey reprised his role as Ernie "Chip" Douglas, from the 1996 movie The Cable Guy, in a commercial for Verizon, which aired during the Super Bowl. In April 2022, Carrey announced that he was considering retirement, saying: "I have enough. I've done enough. I am enough." He said he would return to acting if "angels bring some sort of script that's written in gold ink that says to me that it's going to be really important for people to see". In February 2024, it was announced that Carrey would reprise his role as Dr. Ivo Robotnik in Sonic the Hedgehog 3. A copy of the script for Sonic the Hedgehog 3 was delivered to Carrey written in 24-carat ink in reference to his previous comments. Carrey also plays Ivo Robotnik's grandfather, Gerald Robotnik. Carrey reportedly told an Associated Press reporter that he agreed to return to the Sonic universe because "I need the money, frankly." He later clarified in interviews in December 2024 that he planned to "power rest" rather than retire, while also stating that he was open to continuing his role in the Sonic film series. In March 2026, Carrey was announced to return as Dr. Ivo Robotnik in Sonic the Hedgehog 4 (2027). In August 2026, Carrey was announced to star in the upcoming live-action film The Jetsons, but his role is yet to be confirmed.
Cod has been an important economic commodity in international markets since the Viking period (around 800 AD). Norwegians travelled with dried cod and soon a dried cod market developed in southern Europe. This market has lasted for more than 1,000 years, enduring the Black Death, wars and other crises, and is still an important Norwegian fish trade. The Atlantic "cod" is first attested in Middle English from a document dated 1357; it is an outlier to other Germanic languages whose speakers that also fished and traded it in the same waters gave related names like German: Dorsch, Danish: torsk and Faroese: toskur. However, there is a proposal where Old Norse þoskr may have stabilized with influence of Flemish and Norman metathesized as scot, in which the pluralized les scots (with Norman definite article les) would be rebracketted as les cots thus cots reanalyzed as a plural form of cot or later cod. The Portuguese began fishing cod in the 15th century. Clipfish is widely enjoyed in Portugal. The Basques played an important role in the cod trade, and allegedly found the Canadian fishing banks before Columbus' discovery of America. The North American east coast developed in part due to the vast cod stocks. Many cities in the New England area are located near cod fishing grounds. The fish was so important to the history and development of Massachusetts, the state's House of Representatives hung a wood carving of a codfish, known as the Sacred Cod of Massachusetts, in its chambers.
== Career == In 1979, Limbird joined Vanderbilt University as an Assistant Professor of Pharmacology. She led her own lab for several years, focusing on the actions of epinephrine and norepinephrine in alpha2-adrenergic receptor pathways. Limbird served as Chair of the Department of Pharmacology at the Vanderbilt School of Medicine from 1991-1998, and was the first Associate Vice Chancellor for Research of the Vanderbilt University Medical Center from 1998-2003. With Hal Moses, Limbird was instrumental in determining the 1997 strategic plan for the program. After 25 years at Vanderbilt, Limbird chose to join minority-serving institutions, in hopes of using her scientific administrative, and personal experience to help counter the impact of systemic racism. In 2005, she became Vice President for Research and Chair of the Department of Biomedical Sciences at Meharry Medical College. In 2008, Limbird became Dean of the School of Natural Sciences, Mathematics and Business Administration at Fisk University in Nashville, Tennessee.
Sources: en.wikipedia.org
Hypoglycemia (11 - 12%) - while it was shown to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% less hypoglycemic confirmed episodes in comparison with glimepiride. Uncommon adverse effects between 1 - 10%:
He claimed that on 3 August the third side began to participate in the clashes between the Georgian and South Ossetian forces, firing on both the Georgians and South Ossetians. Illarionov said that the Ossetians do not deny the Georgian reports that the Ossetians violated the ceasefire declared on 7 August by Saakashvili. According to him, by August 2008 South Ossetia had become the most militarised territory per capita in the world, surpassing even North Korea. He also said that the Georgians apparently did not have any plan to invade South Ossetia, only a plan to defend the Georgian villages in South Ossetia. In November 2008, Russian organisation Memorial said there was abundant evidence of mutual shelling before 7 August 2008. The head of Memorial, Oleg Orlov, was in South Ossetia and Georgia for two weeks. He said that firing started on August 1 along the Georgian-South Ossetian border. Orlov said that South Ossetians had attacked Georgian civilians inside South Ossetia and they had used the Tskhinvali headquarters of Russian peacekeeping force as their base. Orlov said that Russia had provoked the Georgian military operation. He added, "But Russian peacekeepers also didn't do their job properly. We know the Russian side gave arms to the Ossetians and that they used them to fire towards Georgia from Russian peacekeeping positions well before August 7." Orlov reported that Russia had begun building the road connecting Tskhinvali with Akhalgori in the spring 2008, long before the war, and it was already completely finished.
== Determination == Death was historically believed to be an event that coincided with the onset of clinical death. It is now understood that death is a series of physical events, not a single one, and determination of permanent death is dependent on other factors beyond simple cessation of breathing and heartbeat. Clinical death that occurs unexpectedly is treated as a medical emergency. CPR is initiated. In a United States hospital, a Code Blue is declared and Advanced Cardiac Life Support procedures used to attempt to restart a normal heartbeat. This effort continues until either the heart is restarted, or a physician determines that continued efforts are useless and recovery is impossible. If this determination is made, the physician pronounces legal death and resuscitation efforts stop. If clinical death is expected due to terminal illness or withdrawal of supportive care, often a Do Not Resuscitate (DNR) or "no code" order is in place. This means that no resuscitation efforts are made, and a physician or nurse may pronounce legal death at the onset of clinical death. A patient with working heart and lungs who is determined to be brain dead can be pronounced legally dead without clinical death occurring. However, some courts have been reluctant to impose such a determination over the religious objections of family members, such as in the Jesse Koochin case. Similar issues were also raised by the case of Mordechai Dov Brody, but the child died before a court could resolve the matter.
Racecadotril, also known as acetorphan, is an antidiarrheal medication which acts as a peripheral enkephalinase inhibitor. Unlike other opioid medications used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect — it reduces the secretion of water and electrolytes into the intestine. It is available in France (where it was first introduced in ~1990) and other European countries (including Germany, Italy, the United Kingdom, Spain, Portugal, Poland, Finland, Slovakia, Russia and Czechia ) as well as most of South America and some South East Asian countries (including China, India and Thailand), but not in the United States. It is sold under the tradename Hidrasec, among others. Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinases.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.